Company research / LXEO

Lexeo Therapeutics, Inc. (LXEO)

Build a valuation ↗↓ Download CSV

CIK 0001907108 · Nasdaq · Biological Products, (No Diagnostic Substances)

Sector Manufacturing
Fiscal year ends Dec 31

For the year ended 2022-12-31, Lexeo Therapeutics, Inc. reported revenue of $654.0K.

Key ratios (year ended 2022-12-31)

-9252.1%

Operating margin

-9063.8%

Net margin

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: 4 · 2026-08-19

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. A dash means a matching observation is unavailable.

Period ended	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue	—	—	—	$654.0K	—
Operating Income	-$109.26M	-$105.77M	-$68.51M	-$60.51M	—
Net Income	-$99.96M	-$98.33M	-$66.39M	-$59.28M	—
EPS (Diluted)	$-1.86	$-3.09	$-12.40	$-36.36	—
Total Assets	$268.69M	$146.94M	$139.81M	$97.08M	—
Total Liabilities	$22.02M	$30.10M	$26.27M	$25.00M	—
Shareholders' Equity	$246.67M	$116.84M	$113.53M	-$112.95M	-$55.60M
Cash & Equivalents	$63.00M	$35.01M	$121.47M	$77.33M	$135.86M
Operating Cash Flow	-$98.56M	-$81.15M	-$59.50M	-$54.56M	—
Capital Expenditures	$397.0K	$481.0K	$115.0K	$672.0K	—
Shares Outstanding	73.00M	33.07M	26.65M	1.61M	—
Weighted Average Diluted Shares	53.65M	31.79M	5.35M	1.63M	—
EPS (Basic)	$-1.86	$-3.09	$-12.40	$-36.36	—